O
1.82
-0.01 (-0.55%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Outlook Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-2.0
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -2.00 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 38.31% |
| 机构持股比例 | 16.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lvw Advisors, Llc | 30 Sep 2025 | 48,235 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 10.00 (Ascendiant Capital, 449.45%) | 购买 |
| 中 | 1.00 (-45.06%) | |
| 低 | 0.500 (HC Wainwright & Co., -72.53%) | 保留 |
| 平均值 | 3.83 (110.44%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 1.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 1.00 (-45.05%) | 保留 | 0.543 |
| HC Wainwright & Co. | 02 Jan 2026 | 0.500 (-72.53%) | 保留 | 0.660 |
| Ascendiant Capital | 22 Dec 2025 | 10.00 (449.45%) | 购买 | 1.84 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合